Use of CGRP receptor antagonists in neuroprotection and neurological disorders
US12103951B2 · kind B2 · utility
0Cited by
20References
10Claims
0Family size
Inventor
Key dates
| Filing date | Jun 14, 2022 |
| Grant date | Oct 1, 2024 |
| Priority date | — |
| Expiry date | Jun 14, 2042 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are treatment methods, including methods of treating nerve damage, methods of neuroprotection, methods of treating glaucoma and methods of lowering LDL levels. The methods generally involve administering to an individual in need thereof an effective amount of a CGRP receptor antagonist peptide or composition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.